title: [The antioxidant action of dalargin on the liver in experimental acute cholestasis].
abstract: Experiments were conducted on 182 rats with acute cholestasis to study the effect of intra-abdominal dalargin injection (10 mcg/kg) with the serotonin antagonist ketanserine (150 mg/kg) on xanthine oxidase (XO) activity and level of lipid peroxidation in the hepatic tissue and on the activity of the hepatospecific enzymes histidase and urokaninase in hepatic tissue and blood serum 1, 3, and 5 hours after the injection. Dalargin reduced XO activity by 32-37% in different periods after the injection, dalargin in combination with ketanserine--by 37-48%. Dalargin reduced the level of lipid peroxidation by 29-35%, and when combined with ketanserine--by 37-49%. The administration of dalargin reveals a distinct tendency towards reduction of the release of the hepatospecific enzymes histidase and urokanase into the blood and increase of their activity in the hepatic tissue. Dalargin with ketanserine produces a similar effect but of a higher degree. These data allow us to speak of the hepatoprotective effect of dalargin, which is potentiated by its injection together with ketanserine. It was found that dalargin (50 mcg/kg, intraperitoneally) increases the leu-enkephalin content in the hepatic tissue more than 3.5 fold one hour after injection.
authors.forename: R N
authors.initials: RN
authors.lastname: Korotkina
authors.forename: E P
authors.initials: EP
authors.lastname: Fomchenkov
authors.forename: N V
authors.initials: NV
authors.lastname: Babkina
authors.forename: V I
authors.initials: VI
authors.lastname: Andreev
authors.forename: B M
authors.initials: BM
authors.lastname: Shloznikov
authors.forename: A A
authors.initials: AA
authors.lastname: Karelin
mesh_terms: D000208:Acute Disease; D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use*; D002779:Cholestasis / Q000188:drug therapy* / Q000201:enzymology; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007650:Ketanserin / Q000627:therapeutic use; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D051381:Rats
chemical_list: D000897:Anti-Ulcer Agents; D000975:Antioxidants; D016308:Enkephalin, Leucine-2-Alanine; D007650:Ketanserin; C040996:enkephalin-Leu, Ala(2)-Arg(6)-
vernacular_title: Antioksidantnoe deĭstvie dalargina na pechen' v usloviiakh ostrogo kholestaza v éksperimente.